Anupam Rasayan India Ltd. issued a formal clarification on February 13, 2026, in response to media reports suggesting plans to acquire a stake in Bliss GVS Pharma Ltd. The company stated explicitly that no such material event or information exists that warrants disclosure under regulatory requirements. Anupam Rasayan confirmed its strict compliance with all existing disclosure norms and declined to comment further on unsubstantiated market speculation.
Company Response to Media Reports
Anupam Rasayan India Ltd. addressed recent news and electronic media reports concerning the Company’s alleged plans to acquire a stake in Bliss GVS Pharma Ltd. The clarification was formally issued on February 13, 2026.
No Material Event Disclosure
In its communication, the management affirmed that there is no material event or information currently in existence that necessitates disclosure under relevant regulations. Furthermore, the Company stated that it does not wish to comment on the specific speculation reported by the news media.
Commitment to Compliance
The management emphasized that the Company has consistently complied, and continues to comply, with all mandatory disclosure norms as per its internal policy regarding material events and information, ensuring transparency whenever required.
The document was signed by Ashish Gupta, Company Secretary and Compliance Officer, confirming the veracity of the statement.
Source: BSE
